Literature DB >> 29155146

HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.

Xuehai Bian1, Zhongxing Liang2, Amber Feng3, Eric Salgado3, Hyunsuk Shim4.   

Abstract

Although histone deacetylase (HDAC) inhibitors have been shown to effectively induce the inhibition of proliferation and migration in breast cancer, the anticancer mechanism remains poorly understood. Our studies show that miR-200c was significantly downregulated in breast cancer cell lines compared to normal cell lines and inversely correlated with the levels of class IIa HDACs and CRKL. HDAC inhibitors and the ectopic expression of miR-200c as tumor suppressors inhibited the proliferation, invasion, and migration of breast cancer cells by downregulating CRKL. These results indicate that the anticancer mechanism of HDAC inhibitor was realized partially by regulating miR-200c via CRKL targeting. Our findings suggest that the HDAC-miR200c-CRKL signaling axis could be a novel diagnostic marker and potential therapeutic target in breast cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; CRKL; HDAC inhibitor; MiR-200c; SAHA

Mesh:

Substances:

Year:  2017        PMID: 29155146      PMCID: PMC5733635          DOI: 10.1016/j.bcp.2017.11.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   6.100


  52 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 2.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

3.  Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals.

Authors:  Shao Wu; Zhi Luo; Peng-Jiu Yu; Hui Xie; Yu-Wen He
Journal:  Biol Chem       Date:  2016-01       Impact factor: 3.915

4.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

Authors:  P N Munster; T Troso-Sandoval; N Rosen; R Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

5.  miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.

Authors:  Jonathon D Roybal; Yi Zang; Young-Ho Ahn; Yanan Yang; Don L Gibbons; Brandi N Baird; Cristina Alvarez; Nishan Thilaganathan; Diane D Liu; Pierre Saintigny; John V Heymach; Chad J Creighton; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2010-11-29       Impact factor: 5.852

Review 6.  Romidepsin for the treatment of cutaneous T-cell lymphoma.

Authors:  Clara Campas-Moya
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

7.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Authors:  Ping Zhu; Elke Martin; Jörg Mengwasser; Peter Schlag; Klaus-Peter Janssen; Martin Göttlicher
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

Review 8.  Emerging significance of estrogen cancer coregulator signaling in breast cancer.

Authors:  M Mann; S Krishnan; R K Vadlamudi
Journal:  Minerva Ginecol       Date:  2012-02

9.  Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.

Authors:  Y H Kim; K A Kwei; L Girard; K Salari; J Kao; M Pacyna-Gengelbach; P Wang; T Hernandez-Boussard; A F Gazdar; I Petersen; J D Minna; J R Pollack
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

10.  Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Authors:  S S Roy; V K Gonugunta; A Bandyopadhyay; M K Rao; G J Goodall; L-Z Sun; R R Tekmal; R K Vadlamudi
Journal:  Oncogene       Date:  2013-08-26       Impact factor: 9.867

View more
  16 in total

Review 1.  MicroRNAs involved in drug resistance of breast cancer by regulating autophagy.

Authors:  Nan Wen; Qing Lv; Zheng-Gui Du
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

Review 2.  Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.

Authors:  Felix Weiss; Douglas Lauffenburger; Peter Friedl
Journal:  Nat Rev Cancer       Date:  2022-01-10       Impact factor: 60.716

3.  Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion.

Authors:  Kyle M Alpha; Weiyi Xu; Christopher E Turner
Journal:  Int Rev Cell Mol Biol       Date:  2020-08-06       Impact factor: 6.813

4.  Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia.

Authors:  Shasha Ren; Jiuzhou Liu; Yun Feng; Zhenyu Li; Liang He; Leilei Li; Xiaozhong Cao; Zhenghua Wang; Yanwu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2019-09-05

5.  CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.

Authors:  Tian Tu; Jia Huang; Miaomiao Lin; Zhen Gao; Xiaoli Wu; Wenjie Zhang; Guangdong Zhou; Wenbo Wang; Wei Liu
Journal:  Int J Mol Med       Date:  2019-09-23       Impact factor: 4.101

Review 6.  The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook.

Authors:  Enrique Hernández-Lemus; Helena Reyes-Gopar; Jesús Espinal-Enríquez; Soledad Ochoa
Journal:  Genes (Basel)       Date:  2019-10-30       Impact factor: 4.096

Review 7.  MicroRNAs and Metastasis.

Authors:  Carla Solé; Charles H Lawrie
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

8.  Overexpression of microRNA-203 can downregulate survivin and function as a potential therapeutic target in papillary thyroid cancer.

Authors:  Xianjiang Wu; Lei Dai; Zhoujing Zhang; Jueru Zheng; Jianpei Zhao
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

Review 9.  Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.

Authors:  Pierre Autin; Christophe Blanquart; Delphine Fradin
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

10.  Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.

Authors:  Jie Wang; Ke-Yong Tian; Ying Fang; Hui-Min Chang; Ya-Nan Han; Fu-Quan Chen
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.